전장 엑솜 시퀀싱 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 워크플로우별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Whole Exome Sequencing Market Growth & Trends:

The global whole exome sequencing market size is expected to reach USD 1,272.5 million by 2030, registering to grow at a CAGR of 18.44% from 2024 to 2030 according to a new report by Grand View Research, Inc. One of the primary factors driving the market is the advancement in technology for whole exome sequencing. High throughput technology is becoming more widely used in clinical diagnostics and research which helps doctors to better understand the exome sequence disorders and made a treatment accordingly. Additionally, the rising prevalence of genetic conditions has enabled the adoption of whole exome sequencing for the investigation of protein coding regions and the derivation of valuable output about genetic variants.

Additionally, the significant increase in research including whole exomes is driven by the availability of data analysis and interpretation software. The use of these tools and software to examine genetic data is easy and it provides a fresh insight into the underlying causes of genetic abnormalities and diseases. For instance, in May 2022, Illumina's subsidiary Grail, announced a partnership with the U.S. Department of Veterans Affairs, to provide their Galleri multi-cancer early detection test to U.S. veterans. This test utilizes whole exome sequences to detect multiple types of cancer in the early stages. This partnership exemplifies how the usage of whole exome sequencing and advanced data analysis tools can enable large-scale genomic research and transform the future of precision medicine.

The market has been significantly impacted by the COVID-19 pandemic. An example of how whole exomes have been used to better understand the virus and its dissemination is the COVID-19 Genomics UK Consortium study. The pandemic has also brought attention to the promise of exome sequence in the fight against infectious diseases, spurring additional investment in this field of study. The entire market is anticipated to develop in the upcoming years despite difficulties brought on by the pandemic in 2020.

Whole Exome Sequencing Market Report Highlights:

• The consumables segment dominated the market in 2024 with a market share of 62.36%. This is due to whole exome sequencing's requirement of a variety of consumable items, including reagents, kits, and sample preparation consumables, which are essential for conducting whole exome sequencing investigations.
• Sequencing by synthesis segment dominated the market in 2024 with a market share of 73.49%. This is due to the effectiveness and affordability of the sequencing by synthesis approach that has increased its appeal.
• The sequencing segment had a dominating presence in the market in 2024 with a market share of 49.90%, due to the growing demand for genetic testing services and personalized medicine. Whole exome sequencing has the ability to analyze large number of genetic data in a less cost, additionally it allows for more comprehensive analysis of genetic variation.
• Drug discovery & development segment dominated the market in 2024 with a market share of 47.38% due to it plays a crucial part in advancing the development of new drugs. Whole exome sequencing has become a compelling method for locating gene variations and disease-causing mutations that can be exploited to create tailored treatments.
• The academic & research institutes segment in whole exome sequencing market dominated the market in 2024, with a share of 47.32%. The dominance of the segment is due to the increasing demand for personalized medicines and healthcare.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Technology Segment
    • 1.1.1.3. Workflow Segment
    • 1.1.1.4. Application Segment
    • 1.1.1.5. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing Prevalence of Genetic Diseases
    • 3.2.1.2. Technological Advancements in Sequencing Platforms and Data Analysis Tools
    • 3.2.1.3. Decreasing Costs of Sequencing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Complexity and Costs Associated with Data Storage, Interpretation & Analysis
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Segment Dashboard
• 4.2. Whole Exome Sequencing Market: Product Movement Analysis
• 4.3. Whole Exome Sequencing Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments Market, 2018 - 2030 (USD Million)
• 4.5. Consumables
  • 4.5.1. Consumables Market, 2018 - 2030 (USD Million)
• 4.6. Services
  • 4.6.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Segment Dashboard
• 5.2. Whole Exome Sequencing Market: Technology Movement Analysis
• 5.3. Whole Exome Sequencing Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. Sequencing by Synthesis
  • 5.4.1. Sequencing By Synthesis Market, 2018 - 2030 (USD Million)
• 5.5. ION Semiconductor Sequencing
  • 5.5.1. ION Semiconductor Sequencing Market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Other Technology Market, 2018 - 2030 (USD Million)

Chapter 6. Workflow Business Analysis

• 6.1. Segment Dashboard
• 6.2. Whole Exome Sequencing Market: Workflow Movement Analysis
• 6.3. Whole Exome Sequencing Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
• 6.4. Pre-Sequencing
  • 6.4.1. Pre-Sequencing Market, 2018 - 2030 (USD Million)
• 6.5. Sequencing
  • 6.5.1. Sequencing Market, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Other Workflow Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Segment Dashboard
• 7.2. Whole Exome Sequencing Market: Application Movement Analysis
• 7.3. Whole Exome Sequencing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 7.4. Clinical Diagnostics
  • 7.4.1. Clinical Diagnostics Market, 2018 - 2030 (USD Million)
• 7.5. Drug Discovery & Development
  • 7.5.1. Drug Discovery & Development Market, 2018 - 2030 (USD Million)
• 7.6. Personalized Medicines
  • 7.6.1. Personalized Medicines Market, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Other Application Market, 2018 - 2030 (USD Million)

Chapter 8. End Use Business Analysis

• 8.1. Segment Dashboard
• 8.2. Whole Exome Sequencing Market: End Use Movement Analysis
• 8.3. Whole Exome Sequencing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Academic And Research Institutes
  • 8.4.1. Academic And Research Institutes Market, 2018 - 2030 (USD Million)
• 8.5. Hospitals & Clinics
  • 8.5.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
• 8.6. Pharmaceutical & Biotechnology Companies
  • 8.6.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
• 8.7. Others
  • 8.7.1. Other End use Market, 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. North America
  • 9.3.1. North America Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Target Disease Prevalence
    • 9.3.2.3. Competitive Scenario
    • 9.3.2.4. Regulatory Framework
    • 9.3.2.5. U.S. Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Regulatory Framework
    • 9.3.3.5. Canada Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Competitive Scenario
    • 9.3.4.4. Regulatory Framework
    • 9.3.4.5. Mexico Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Competitive Scenario
    • 9.4.2.4. Regulatory Framework
    • 9.4.2.5. UK Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. Regulatory Framework
    • 9.4.3.5. Germany Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Regulatory Framework
    • 9.4.4.5. France Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Regulatory Framework
    • 9.4.5.5. Italy Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Regulatory Framework
    • 9.4.6.5. Spain Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Regulatory Framework
    • 9.4.7.5. Denmark Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Target Disease Prevalence
    • 9.4.8.3. Competitive Scenario
    • 9.4.8.4. Regulatory Framework
    • 9.4.8.5. Sweden Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Target Disease Prevalence
    • 9.4.9.3. Competitive Scenario
    • 9.4.9.4. Regulatory Framework
    • 9.4.9.5. Norway Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Competitive Scenario
    • 9.5.2.4. Regulatory Framework
    • 9.5.2.5. Japan Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. Regulatory Framework
    • 9.5.3.5. China Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Competitive Scenario
    • 9.5.4.4. Regulatory Framework
    • 9.5.4.5. India Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.5. Australia
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Competitive Scenario
    • 9.5.5.4. Regulatory Framework
    • 9.5.5.5. Australia Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Competitive Scenario
    • 9.5.6.4. Regulatory Framework
    • 9.5.6.5. Thailand Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5.7. South Korea
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Competitive Scenario
    • 9.5.7.4. Regulatory Framework
    • 9.5.7.5. South Korea Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Competitive Scenario
    • 9.6.2.4. Regulatory Framework
    • 9.6.2.5. Brazil Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Competitive Scenario
    • 9.6.3.4. Regulatory Framework
    • 9.6.3.5. Argentina Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Competitive Scenario
    • 9.7.2.4. Regulatory Framework
    • 9.7.2.5. South Africa Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Competitive Scenario
    • 9.7.3.4. Regulatory Framework
    • 9.7.3.5. Saudi Arabia Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Target Disease Prevalence
    • 9.7.4.3. Competitive Scenario
    • 9.7.4.4. Regulatory Framework
    • 9.7.4.5. UAE Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Target Disease Prevalence
    • 9.7.5.3. Competitive Scenario
    • 9.7.5.4. Regulatory Framework
    • 9.7.5.5. Kuwait Whole Exome Sequencing Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Share Analysis, 2024
• 10.4. Company Profiles/Listing
  • 10.4.1. Thermo Fisher Scientific, Inc.
    • 10.4.1.1. Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. Illumina, Inc.
    • 10.4.2.1. Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. Agilent Technologies, Inc
    • 10.4.3.1. Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. BGI
    • 10.4.4.1. Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Strategic Initiatives
  • 10.4.5. PacBio
    • 10.4.5.1. Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. Oxford Nanopore Technologies plc.
    • 10.4.6.1. Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. Azenta US Inc. (GENEWIZ)
    • 10.4.7.1. Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. CD Genomics
    • 10.4.8.1. Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. Novogene Co, Ltd
    • 10.4.9.1. Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. Eurofins Genomics
    • 10.4.10.1. Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Strategic Initiatives